跳至主要内容
临床试验/NCT00205491
NCT00205491已完成4 期

Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)

Virginia Commonwealth University2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2004年10月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
100
试验地点
2
主要终点
Score on the Hamilton Rating Scale for Depression (Ham-D)at 12 weeks.

研究概览

简要总结

The purpose of this study is to determine if treatment with venlafaxine reduces symptoms of depression in persons with traumatic brain injury.

详细描述

The study evaluates the benefits of a promising antidepressant medication for the treatment of persons with traumatic brain injury (TBI) and major depressive disorder (MDD). The study is a randomized, double-blind, placebo-controlled trial of venlafaxine (a serotonin and norepinephrine reuptake inhibitor, also known as Effexor). Venlafaxine has been well established in the treatment of MDD in healthy individuals and is a recommended depression treatment agent for persons with TBI. By using a rigorous scientific methodology, this study will be an important first step in advancing the treatment of depression in this population beyond general impressions to proven treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must have a documented traumatic brain injury (TBI), defined as damage to brain tissue caused by an external mechanical force as evidenced by: loss of consciousness due to brain trauma, or post traumatic amnesia (PTA), or skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical examination or mental status examination.
  • Age 18 years or older
  • At least three months postinjury
  • Presence of major depressive disorder (MDD), as defined by Structured Clinical Interview for DSM-IV (SCID) interview
  • Hamilton Depression Rating Scale (Ham-D) scores of 18 or greater on two consecutive evaluations (screening and baseline)

排除标准

  • Individuals under 18 years of age
  • Pregnancy, as determined by urine pregnancy screen
  • Prisoners
  • Individuals who are institutionalized
  • Individuals who are not cognitively capable of completing the SCID interview and the Ham-D
  • Unstable medical condition, defined as any significant medical condition likely to require hospitalization during the study period, or requiring adjustment in medications in the past month
  • Active suicidality
  • Severe depression that, in the investigator's professional opinion, will likely require hospitalization during the study time period
  • Diagnosis of bipolar disorder, as defined by SCID interview
  • Diagnosis of schizophrenia or other psychotic disorder, as defined by SCID interview, other than major depression with psychotic features
  • Active drug or alcohol abuse within the past 3 months, as defined by SCID interview
  • Dysphagia sufficient to preclude use of oral medications
  • Known hypersensitivity to venlafaxine
  • Use of monamine oxidase inhibitors (MAOI) within the past month
  • Treatment with antidepressant medication within the past 3 months
  • Concomitant administration of medications that interact with venlafaxine to a clinically significant degree

结局指标

主要结局

Score on the Hamilton Rating Scale for Depression (Ham-D)at 12 weeks.

次要结局

  • Scores on cognitive and psychomotor tests at 12 weeks.
  • Scores on a satisfaction with life measure and a functional measure at 12 weeks.

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验